Kenya is the bigger Alzheimer Drugs market: $3.5 Bn against $91 Mn in 2023, about 38 times as large.
India grows faster: 9.8% a year, against 7.9%. The gap still grows from $3.4 Bn to $7.3 Bn by 2033.
Clinical research: 0 active trials in Kenya, 7 in India.
| Measure |  Kenya |  India |
|---|---|---|
| Market size, 2023 | $3.5 Bn | $91 Mn |
| Market size, 2033 projected | $7.5 Bn | $232 Mn |
| Growth a year (CAGR) | 7.9% | 9.8% |
| Money added, 2023–2033 | $4 Bn | $141 Mn |
| Size rank of 24 countries | #1 | #13 |
| Market per person, 2023 | $61 | $0.06 |
| Active clinical trials | 0 | 7 |
| Full report | Kenya report | India report |
Year by year, 2023 to 2033
Kenya India · values between 2023 and 2033 are projected from the 2023 size and the CAGR.
Quick answers
Which is bigger in Alzheimer Drugs, Kenya or India?
Kenya is the bigger Alzheimer Drugs market: $3.5 Bn against $91 Mn in 2023, about 38 times as large.
Which grows faster in Alzheimer Drugs, Kenya or India?
India grows faster: 9.8% a year, against 7.9%. The gap still grows from $3.4 Bn to $7.3 Bn by 2033.
More Alzheimer Drugs comparisons
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide. Population: World Bank.